Quest Diagnostics (DGX) fundamentals: P/E, valuation, undervalued?
Quest Diagnostics · Health Care · ref. ETF XLV · price $244.61
In short — Quest Diagnostics trades at 26.0× earnings (P/E), 20.3× forward, with a net margin of 9.2 % and revenue growth of +10 %. Read: Fairly valued (P/E 20 in line with ~15% growth (PEG 1.4)).
Is Quest Diagnostics stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$244.61+36.5% over range
Aug 28, 25low $173.49 · high $245Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
29% recommend buying · 7 analysts
Valuation : Fairly valued — P/E 20 in line with ~15% growth (PEG 1.4)
Valuation
26.0
P/E (price/earnings)
20.3
Forward P/E
1.73
PEG
3.6
Price/book (P/B)
$27.0B
Market cap
9.41
EPS
Profitability & growth
9.2 %
Net margin
+10 %
Revenue growth
+15 %
Earnings growth
$6.4B
Total debt
Quest Diagnostics income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $9.9B | $946M | 9.6 % |
| 2023 | $9.3B | $854M | 9.2 % |
| 2024 | $9.9B | $871M | 8.8 % |
| 2025 | $11.0B | $992M | 9.0 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Quest Diagnostics's P/E and is the stock undervalued? What's a good P/E?
Quest Diagnostics's P/E is 26.0 (forward 20.3). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is Quest Diagnostics profitable?
Quest Diagnostics has a net margin of 9.2 % (EPS 9.41). The company is profitable.
Is DGX stock expensive?
Our read: "Fairly valued" — P/E 20 in line with ~15% growth (PEG 1.4). Cross-check with growth and sector.
💬 A question about Quest Diagnostics? The JPI assistant answers using our backtest data.
Keep exploring Quest Diagnostics